Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Core Viewpoint - Nexalin Technology, Inc. has validated its proprietary neurostimulation technology, Deep Intracranial Frequency Stimulation (DIFS™), through rigorous peer-reviewed clinical research across various neurological and psychiatric conditions, differentiating it from superficial neurostimulation techniques [1][8]. Group 1: Clinical Applications - Nexalin's clinical research spans multiple conditions including insomnia, depression, traumatic brain injury, PTSD, Alzheimer's disease, and ADHD, supporting its clinical business plan with the FDA [2][6]. - The technology has shown objective normalization of abnormal brain activity and network function, validated through patient symptom surveys and advanced neuroimaging techniques [3][4]. Group 2: Research Validation - Nexalin's studies utilize advanced imaging modalities such as MRI, fMRI, MEG, EEG, and PET to demonstrate the engagement of deep brain networks associated with mental health disorders, contrasting with superficial stimulation methods [4][8]. - A recent randomized, double-blind, sham-controlled trial published in Molecular Psychiatry indicated that DIFS™ neurostimulation led to objective normalization of gamma-frequency brain activity, improving communication across brain networks related to attention, mood, and cognitive control [5][6]. Group 3: Mechanism of Action - Nexalin's DIFS™ technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks, with objective imaging data supporting its efficacy [5][8]. - The technology has demonstrated the ability to deliver frequency-specific stimulation that penetrates deep brain structures, influencing large-scale neural networks without invasive procedures [7][9]. Group 4: Future Directions - Nexalin aims to build a comprehensive, imaging-supported body of evidence in non-invasive brain stimulation, positioning its DIFS™ technology as a scientifically grounded approach to address complex mental health and neurological disorders [9][10].